Patient preferences for treatment in steroid resistant ulcerative colitis – a discrete-choice experiment

References

• Brooks AJ, Rowse G, Ryder A, et al. Systematic review: psychological morbidity in young people with inflammatory bowel disease – risk factors and impacts. Aliment Pharmacol The. 2016;44(1):3–15.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on the development of new medicinal products for the treatment of Crohn’s Disease; 2016 [cited 2020 Mar 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211430.pdf.
   Google Scholar
• Ho G-T, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24(2):319–330.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Louis E, Ramos-Goñi JM, Cuervo J, et al. A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective. Patient. 2020;13(3):317–325.
   PubMedGoogle Scholar
• Baars JE, Markus T, Kuipers EJ, et al. Patients’ preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion. 2010;81(2):113–119.
   PubMed Web of Science ®Google Scholar
• Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4(9):1135–1142.
   PubMed Web of Science ®Google Scholar
• Casellas F, Guinard Vicens D, García-López S, et al. Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations. Eur J Gastroenterol Hepatol. 2020;32(12):1514–1522.
   PubMed Web of Science ®Google Scholar
• Bager P, Julsgaard M, Vestergaard T, et al. Adherence and quality of care in IBD. Scand J Gastroenterol. 2016;51(11):1326–1331.
   PubMed Web of Science ®Google Scholar
• Lindfors P, Axelsson E, Engstrand K, et al. Online education is non-inferior to group education for irritable bowel syndrome: a randomized trial and patient preference trial. Clin Gastroenterol Hepatol. 2021;19(4):743–751. e1.
   PubMed Web of Science ®Google Scholar
• Abraham NS, Naik AD, Street RL. Shared decision making in GI clinic to improve patient adherence. Clin Gastroenterol Hepatol. 2012;10(8):825–827.
   PubMed Web of Science ®Google Scholar
• de Bekker‐Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145–172.
   PubMed Web of Science ®Google Scholar
• Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient. 2013;6(4):241–255.
   PubMedGoogle Scholar
• Boeri M, Myers K, Ervin C, et al. Patient and physician preferences for ulcerative colitis treatments in the United States. Clin Exp Gastroenterol. 2019;12:263–278.
   PubMed Web of Science ®Google Scholar
• Almario CV, Keller MS, Chen M, et al. Optimizing selection of biologics in inflammatory bowel disease: development of an online patient decision aid using conjoint analysis. Am J Gastroenterol. 2018;113(1):58–71.
   PubMed Web of Science ®Google Scholar
• Patel DB, van Deen WK, Almario CV, et al. Assessing patient decision-making on biologic and small-molecule therapies in inflammatory bowel diseases: insights from a conjoint analysis in the United States, Canada, and the United Kingdom. Inflammatory Bowel Dis. 2021;27(10):1593–1601.
   PubMed Web of Science ®Google Scholar
• Wijnands AM, te Groen M, Peters Y, et al. Patients prioritize a low-volume bowel preparation in colitis-associated colorectal cancer surveillance: a discrete choice experiment. Inflammatory Bowel Dis. 2021;27(9):1–8.
   PubMed Web of Science ®Google Scholar
• Barr A, et al. P96 factors influencing treatment preferences in steroid resistant ulcerative colitis–a qualitative interview study. Gut. 2021;70:A90-A91.
   Google Scholar
• Dalton J. Great big agile: dot voting. Waterford: Springer; 2019. p. 165–166.
   Google Scholar
• Metrics C. Ngene 1.2 user manual & reference guide. Sydney, Australia: Choice Metrics; 2018.
   Google Scholar
• Carlsson F, Martinsson P. Design techniques for stated preference methods in health economics. Health Econ. 2003;12(4):281–294.
   PubMed Web of Science ®Google Scholar
• Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics. 2008;26(8):661–677.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Lytras T, Nikolopoulos G, et al. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):454–465.
   PubMed Web of Science ®Google Scholar
• Ormerod CR. The IBD control questionnaire: the development and psychometric validation of a questionnaire for measuring inflammatory bowel disease control from the patient's perspective. Liverpool (UK): University of Liverpool; 2019.
   Google Scholar
• Devlin NJ, Shah KK, Feng Y, et al. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.
   PubMed Web of Science ®Google Scholar
• Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Vol. 11. Netherland: Springer Science & Business Media; 2007.
   Google Scholar
• de Bekker-Grob EW, Donkers B, Jonker MF, et al. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373–384.
   PubMedGoogle Scholar
• Orme B. Getting started with conjoint analysis: strategies for product design and pricing research second edition. Madison: Research Publishers; 2010.
   Google Scholar
• Lancsar E, Louviere J, Flynn T. Several methods to investigate relative attribute impact in stated preference experiments. Soc Sci Med. 2007;64(8):1738–1753.
   PubMed Web of Science ®Google Scholar
• King D, Reulen RC, Thomas T, et al. Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018. Aliment Pharmacol Ther. 2020;51(10):922–934.
   PubMed Web of Science ®Google Scholar
• Janssen MF, Szende A, Cabases J, et al. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205–216.
   PubMed Web of Science ®Google Scholar
• Kotwani P, Terdiman J, Lewin S. Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience. J Crohns Colitis. 2020;14(7):1026–1028.
   PubMed Web of Science ®Google Scholar
• Bewtra M, Kilambi V, Fairchild AO, et al. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis. 2014;20(1):103–114.
   PubMed Web of Science ®Google Scholar
• Bewtra M, Reed SD, Johnson FR, et al. Variation among patients with Crohn's disease in benefit vs risk preferences and remission time equivalents. Clin Gastroenterol Hepatol. 2020;18(2):406–414. e7.
   PubMed Web of Science ®Google Scholar
• Bewtra M, Fairchild AO, Gilroy E, et al. Inflammatory bowel disease patients' willingness to accept medication risk to avoid future disease relapse. Am J Gastroenterol. 2015;110(12):1675–1681.
   PubMed Web of Science ®Google Scholar
• Gordon JP, McEwan PC, Maguire A, et al. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015;27(7):804–812.
   PubMed Web of Science ®Google Scholar
• Ratcliffe J, Longworth L. Investigating the structural reliability of a discrete choice experiment within health technology assessment. Int J Technol Assess Health Care. 2002;18(1):139–144.
   PubMed Web of Science ®Google Scholar
• Selinger CP, Robinson A, Leong RW. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opin Drug Saf. 2011;10(6):863–870.
   PubMed Web of Science ®Google Scholar